This analysis of the FINEARTS-HF trial identifies that while finerenone increases hypotension risk in HFmrEF and HFpEF patients, its clinical benefits persist. The study highlights key predictors of hypotension, such as low baseline blood pressure and advanced age, emphasizing the need for vigilant clinical monitoring.